• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

638.88 -3.71 (-0.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
May 22, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
May 21, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
May 20, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
May 18, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
May 15, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 15, 2026
Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world’s largest pre-college STEM competition 
From Society For Science
Via GlobeNewswire
News headline image
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
May 08, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
May 05, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Reports First Quarter 2026 Financial and Operating Results
April 29, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
April 23, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
April 23, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
April 22, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
April 21, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentations
April 20, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Telix and Regeneron Announce Strategic Radiopharma Collaboration
April 13, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Regeneron and Telix Announce Strategic Radiopharma Collaboration
April 13, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
April 13, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
April 02, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
April 02, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
March 25, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
March 24, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
March 09, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentation
March 05, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
February 27, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
February 26, 2026
From Society For Science
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
February 24, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
February 19, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentations
February 11, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
February 10, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 02, 2026
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap